MX2022007929A - Coagonistas de triazol grapados de los receptores de glucagon y glp-1. - Google Patents
Coagonistas de triazol grapados de los receptores de glucagon y glp-1.Info
- Publication number
- MX2022007929A MX2022007929A MX2022007929A MX2022007929A MX2022007929A MX 2022007929 A MX2022007929 A MX 2022007929A MX 2022007929 A MX2022007929 A MX 2022007929A MX 2022007929 A MX2022007929 A MX 2022007929A MX 2022007929 A MX2022007929 A MX 2022007929A
- Authority
- MX
- Mexico
- Prior art keywords
- glp
- glucagon
- agonists
- receptors
- stapled
- Prior art date
Links
- 108010063919 Glucagon Receptors Proteins 0.000 title abstract 3
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 title abstract 3
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 title abstract 3
- 102000051325 Glucagon Human genes 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title abstract 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title abstract 2
- 229960004666 glucagon Drugs 0.000 title abstract 2
- 150000003852 triazoles Chemical class 0.000 title 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 2
- 102100040890 Glucagon receptor Human genes 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19425098.1A EP3842061A1 (en) | 2019-12-23 | 2019-12-23 | Stapled triazole co-agonists of the glucagon and glp-1 receptors |
| PCT/US2020/065796 WO2021133644A1 (en) | 2019-12-23 | 2020-12-18 | Stapled triazole co-agonists of the glucagon and glp-1 receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022007929A true MX2022007929A (es) | 2022-09-29 |
Family
ID=69326342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022007929A MX2022007929A (es) | 2019-12-23 | 2020-12-18 | Coagonistas de triazol grapados de los receptores de glucagon y glp-1. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230063794A1 (https=) |
| EP (2) | EP3842061A1 (https=) |
| JP (1) | JP2023508349A (https=) |
| KR (1) | KR20220119475A (https=) |
| CN (1) | CN115226391A (https=) |
| AU (1) | AU2020412677A1 (https=) |
| BR (1) | BR112022012499A2 (https=) |
| CA (1) | CA3162800A1 (https=) |
| MX (1) | MX2022007929A (https=) |
| WO (1) | WO2021133644A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024532362A (ja) * | 2021-08-27 | 2024-09-05 | イエール ユニバーシティ | 細胞外タンパク質の分子分解誘導剤 |
| WO2023028590A1 (en) | 2021-08-27 | 2023-03-02 | Yale University | Molecular degraders of extracellular proteins |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| AR008789A1 (es) | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
| US6268343B1 (en) * | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| US6054587A (en) | 1997-03-07 | 2000-04-25 | Metabasis Therapeutics, Inc. | Indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
| DE69819311T2 (de) | 1997-03-07 | 2004-07-29 | Metabasis Therapeutics Inc., San Diego | Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase |
| US6284748B1 (en) | 1997-03-07 | 2001-09-04 | Metabasis Therapeutics, Inc. | Purine inhibitors of fructose 1,6-bisphosphatase |
| US6613942B1 (en) | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| BR9810378A (pt) | 1997-07-01 | 2000-08-29 | Novo Nordisk As | Composto,uso do mesmo, composição farmacêutica, e, processos de tratar a diabete do tipo i ou do tipo ii, de tratar a hiperglicemia, e de diminuir a glicose do sangue em um mamìfero |
| KR100818845B1 (ko) | 1998-09-09 | 2008-04-01 | 메타베이시스 테라퓨틱스, 인크. | 신규한 프럭토스 1,6-비스포스파타제의 헤테로방향족 억제제 |
| DE60023492T2 (de) | 1999-05-17 | 2006-07-20 | Novo Nordisk A/S | Glucagon antagonisten/inverse agonisten |
| US6677136B2 (en) * | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
| AU7705601A (en) | 2000-07-25 | 2002-02-05 | Merck & Co Inc | N-substituted indoles useful in the treatment of diabetes |
| EP1357908A4 (en) | 2001-01-30 | 2009-07-15 | Merck & Co Inc | "ACYLSULFAMIDES FOR THE TREATMENT OF FATIBILITY, DIABETES AND LIPID DISORDERS" |
| GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| AR040241A1 (es) | 2002-06-10 | 2005-03-23 | Merck & Co Inc | Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia |
| CN100457730C (zh) | 2002-08-29 | 2009-02-04 | 默克公司 | 具有抗糖尿病活性的吲哚化合物 |
| EP1546142A4 (en) | 2002-08-29 | 2007-10-17 | Merck & Co Inc | INDOLES HAVING ANTIDIABETIC EFFECT |
| JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
| AU2004207444B2 (en) | 2003-01-17 | 2008-07-31 | Merck & Co., Inc. | N-cyclohexylaminocarbonyl benzenesulfonamide derivatives |
| EP1888031B1 (en) * | 2005-06-06 | 2013-01-23 | Camurus Ab | Glp-1 analogue formulations |
| ATE553124T1 (de) | 2005-06-13 | 2012-04-15 | Imp Innovations Ltd | Oxyntomodulinanaloga und ihre wirkungen auf das fressverhalten |
| US8175737B2 (en) | 2006-07-19 | 2012-05-08 | Freescale Semiconductor, Inc. | Method and apparatus for designing and integrated circuit |
| CA2677932A1 (en) * | 2007-02-15 | 2008-08-21 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| CN101743616B (zh) | 2007-06-28 | 2012-02-22 | 株式会社半导体能源研究所 | 半导体装置的制造方法 |
| CA2691010A1 (en) | 2007-06-28 | 2008-12-31 | Merck Frosst Canada Ltd. | Substituted fused pyrimidines as antagonists of gpr105 activity |
| EP2178537A4 (en) | 2007-07-19 | 2011-08-17 | Merck Sharp & Dohme | BETA-CARBOLIN DERIVATIVES AS ANTIDIBLE COMPOUNDS |
| US20110301079A1 (en) | 2007-09-21 | 2011-12-08 | Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Neuromedin u receptor agonists and uses thereof |
| AR072160A1 (es) * | 2008-06-17 | 2010-08-11 | Univ Indiana Res & Tech Corp | Co-agonistas del receptor de glucagon/glp-1 |
| WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
| US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| RS56173B1 (sr) * | 2011-06-22 | 2017-11-30 | Univ Indiana Res & Tech Corp | Koagonisti receptora za glukagon/glp-1 receptora |
| KR20140043793A (ko) | 2011-06-22 | 2014-04-10 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루카곤/glp-1 수용체 공동-작용물질 |
| CA2935026C (en) * | 2014-01-15 | 2018-11-13 | Fyziologicky Ustav Akademie Ved Cr, V.V.I. | Lipidated prolactin-releasing peptides for lowering blood glucose |
| CN107108715A (zh) * | 2014-10-24 | 2017-08-29 | 默沙东公司 | 胰高血糖素和glp‑1受体的共激动剂 |
| EP3377521A4 (en) * | 2015-10-27 | 2019-05-01 | Merck Sharp & Dohme Corp. | LONG-ACTING CO AGONISTS OF GLUCAGON AND GLP-1 RECEPTORS |
| WO2017189342A1 (en) * | 2016-04-26 | 2017-11-02 | Merck Sharp & Dohme Corp. | Insulin dimer-incretin conjugates |
| US11566057B2 (en) | 2017-09-25 | 2023-01-31 | Merck Sharp & Dohme Llc | Long-acting co-agonists of the glucagon and GLP-1 receptors |
| CN109836503B (zh) * | 2017-11-24 | 2022-09-16 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的多重活性蛋白 |
| CN109836488B (zh) * | 2017-11-24 | 2022-08-23 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的胰高血糖素类似物 |
| WO2019157362A1 (en) * | 2018-02-09 | 2019-08-15 | Healthtell Inc. | Array-based cyclic peptide libraries |
-
2019
- 2019-12-23 EP EP19425098.1A patent/EP3842061A1/en not_active Withdrawn
-
2020
- 2020-12-18 KR KR1020227025623A patent/KR20220119475A/ko active Pending
- 2020-12-18 JP JP2022538471A patent/JP2023508349A/ja active Pending
- 2020-12-18 CN CN202080096783.1A patent/CN115226391A/zh active Pending
- 2020-12-18 EP EP20904872.7A patent/EP4081243A4/en active Pending
- 2020-12-18 BR BR112022012499A patent/BR112022012499A2/pt unknown
- 2020-12-18 MX MX2022007929A patent/MX2022007929A/es unknown
- 2020-12-18 US US17/785,287 patent/US20230063794A1/en active Pending
- 2020-12-18 CA CA3162800A patent/CA3162800A1/en active Pending
- 2020-12-18 WO PCT/US2020/065796 patent/WO2021133644A1/en not_active Ceased
- 2020-12-18 AU AU2020412677A patent/AU2020412677A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115226391A (zh) | 2022-10-21 |
| BR112022012499A2 (pt) | 2022-09-06 |
| US20230063794A1 (en) | 2023-03-02 |
| JP2023508349A (ja) | 2023-03-02 |
| EP4081243A4 (en) | 2024-01-10 |
| KR20220119475A (ko) | 2022-08-29 |
| EP3842061A1 (en) | 2021-06-30 |
| EP4081243A1 (en) | 2022-11-02 |
| WO2021133644A1 (en) | 2021-07-01 |
| CA3162800A1 (en) | 2021-07-01 |
| AU2020412677A1 (en) | 2022-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017500761A1 (en) | Co-agonists of glucagon and glp-1 receptors | |
| MX2024010201A (es) | Analogos de incretina y sus usos. | |
| MX2025003745A (es) | Analogos de incretina y sus usos | |
| PH12021552557A1 (en) | Glp-1r agonists and uses thereof | |
| PH12017502359A1 (en) | Glucagon and glp-1 co-agonist compounds | |
| MX2018005193A (es) | Proteinas de doble funcion y composicion farmaceutica que comprende las mismas. | |
| JOP20220153A1 (ar) | نظائر الإنكرتين واستخداماتها | |
| EA201790124A1 (ru) | Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения | |
| EA201400056A1 (ru) | Вещества, связывающие ядерные рецепторы | |
| MX2015001500A (es) | Compuestos antidiabeticos triciclicos. | |
| AU2015263620A8 (en) | Antidiabetic tricyclic compounds | |
| PH12019550226A1 (en) | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | |
| WO2018218044A3 (en) | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | |
| EP4623929A3 (en) | Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis | |
| MX2022007929A (es) | Coagonistas de triazol grapados de los receptores de glucagon y glp-1. | |
| EP4596044A3 (en) | Combination therapy of gpr119 agonists and dpp-4 inhibitors | |
| WO2016168553A8 (en) | Deuterated obeticholic acid | |
| WO2016168388A3 (en) | Therapies for obesity, diabetes and related indications | |
| MX2022007928A (es) | Co-agonistas de olefina engrapados de los receptores de glucagon y glp-1. | |
| MX2022007926A (es) | Coagonistas lactamicos grapados de los receptores de glucagon y glp-1. | |
| MX2022013230A (es) | Analogos de glucagon como agonistas de accion prolongada del receptor de glp-1/glucagon para usarse en el tratamiento de enfermedad del higado graso y esteatohepatitis. | |
| EA201990883A1 (ru) | Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения | |
| PH12020551900A1 (en) | Novel compound exhibiting enteropeptidase inhibitory activity | |
| TH1701002228A (th) | อะโกนิสต์ร่วมของกลูคากอนและ glp-1 รีเซปเตอร์ | |
| UA104000C2 (ru) | Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения |